MON-609 Use of a Continuous Glucose Monitor System (CGM) in Latinx Patients with Type 2 Diabetes (TD2) Improves A1c without an Effect on Weight: Real Life Observational Experience

Abstract Disclosure: L. Ramirez Garcia: None. A. Thatte: None. C. Gomez: None. L.A. Wright: Genentech, Inc., Patient Advisory Board. Background: Continuous Glucose Monitoring (CGM) has emerged as a powerful tool in managing Type 2 Diabetes (T2D), offering real-time insights into glucose fluctuations and allowing patients and their providers to better understand the effects of lifestyle changes and medication on their glycemic control. The impact of CGM on A1c and BMI has not been extensively studied in Latinx populations. We aimed to evaluate whether CGM utilization in Latinx patients with T2D results in improved A1c levels and reduced BMI, as surrogates of lifestyle modifications plus the effect on provider-driven therapeutic modifications such as the addition of hypoglycemic agents (HA). Methods: One-year observational retrospective study of Latinx patients with T2D. We obtained Age, gender, CGM use and metrics: average glucose, time in range (TIR), time below range (TBR), time above range (TAR), BMI, A1c, and HA at baseline and at 12-months. Paired-t-test and independent t-test, SPSS were used for statistical analysis. Results: Twenty-nine CGM users: age 54.3±13.2, 67% female, BMI 34.1±6.5 baseline, 34.7±8.2 at 12-months, p=0.2. Baseline A1c 8.9%±1.6, 8.1±1.6 at 12-months, p=0.02. Mean glucose was 202.2±58.3 mg/dl at baseline and 173.1±34.5 mg/dl at 12 months, p= 0.001. TIR went from 46.9%±26.5% to 60.3%±20.8%, p= 0.003, TAR went from 52.4%±26.8% to 39.0%±21.3%, p = 0.002, TBR went from 0.8%±1.6% to 0.9%±1.7%, p=0.556 and CV went from 29.3%±6.4% to 31.3%±6.5%, p=0.053. Glucagon-Like-peptide-1 Receptor agonist (GLP-1RA) use increased by 27.5%, p=0.003; Sodium-Glucose-Cotransporter2-inhibitors (SGLT2-Inh) by 13.8%, p=0.04 at 12-months. Total daily units of insulin (TDUI) baseline 99.7±66.5, 97.6±65.5 at 12-months, p=0.7. Twenty-eight Non-CGM users: Age 52.9±12.1, 44% female, BMI 35.3±9.4 baseline, 36±9.3 at 12-months, p=0.2. Baseline A1c 8.8%±1.6, 8.5±1.6 at 12-months, p=0.06. GLP-1RA use increased 17.9%, p=0.02; SGLT2-Inh 7.2%, p=0.16. TDUI baseline 78.6±69.5, 65.6±47.5 at 12-months, p=0.07.There was no change in BMI between groups; A1c decreased in both, significant only in CGM-users. There was a statistically significant increase within groups of GLP-1 RA and SGLT-2 inh use, but no difference when comparing CGM users vs Non-CGM users: p=0.08 for GLP-1RA, p=0.9 for SGLT2-inh. There was a reduction in TDUI in both groups, but more so in Non-CGM-users, p=0.04. Conclusion: In Latinx patients with T2D, CGM users had a reduction in A1c and higher total daily use of insulin when compared to non-CGM users, without an increased risk of hypoglycemia (TBR) or weight gain. Our results underscore the utility of CGM to optimize glycemic control. Longer CGM use may be needed for a beneficial effect in BMI. Offering and supporting use of CGM in the Latinx population is one tool to improve diabetes care and reduce health inequities. Presentation: Monday, July 14, 2025